Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NICE Issues Technology Appraisal Guidance for Ibrutinib for Previously Treated CLL and Untreated CLL with 17p Deletion or TP53 Mutation

It is recommended in adults who have had at least one prior therapy or who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable
27 Jan 2017
Cytotoxic Therapy
Haematological Malignancies

On 25 January 2017, the NICE issued technology appraisal guidance in which recommended ibrutinib alone within its marketing authorisation as an option for treating chronic lymphocytic leukaemia (CLL) in adults who have had at least one prior therapy or who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and only when the company provides ibrutinib with the discount agreed in the patient access scheme.

The appraisal committee concluded that idelalisib plus rituximab was the most relevant comparator and, for those who cannot take idelalisib plus rituximab, best supportive care was the best comparator in both populations. The appraisal committee was aware that it had not been presented with evidence comparing ibrutinib with best supportive care.

The appraisal committee concluded that ibrutinib offered a more preferable toxicity profile, and was likely to offer progression-free and overall survival benefits compared with idelalisib plus rituximab, but was mindful that the extent of this benefit was uncertain.

No evidence was presented for ibrutinib compared with best supportive care. However, the appraisal committee concluded that it was likely that ibrutinib would be more effective compared with best supportive care than when compared with idelalisib plus rituximab.

The appraisal committee agreed that ibrutinib represented an important and effective treatment in CLL. It was satisfied that, in both populations of this appraisal, the incremental cost-effectiveness ratios (ICERs) for ibrutinib fell within the range normally considered as a cost-effective use of NHS resources for a treatment that fulfils the end-of-life criteria, when incorporating the confidential updated patient access scheme for ibrutinib and the existing patient access scheme for idelalisib. 

Last update: 27 Jan 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.